-
M129386-500mgMilnacipran inhibits both norepinephrine transporter (NET) and norepinephrine transporter (SERT) with IC50 of 77 nM and 420 nM, respectively.
-
M129386-50mgMilnacipran inhibits both norepinephrine transporter (NET) and norepinephrine transporter (SERT) with IC50 of 77 nM and 420 nM, respectively.
-
M129386-5gMilnacipran inhibits both norepinephrine transporter (NET) and norepinephrine transporter (SERT) with IC50 of 77 nM and 420 nM, respectively.
-
M129587-100mgProduct Application:It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. Milrinone inhibits the action of phosphodiesterase-3 preventing degradation of cAMP. The corresponding increase in
-
M129587-1gProduct Application:It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. Milrinone inhibits the action of phosphodiesterase-3 preventing degradation of cAMP. The corresponding increase in
-
M129587-250mgProduct Application:It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. Milrinone inhibits the action of phosphodiesterase-3 preventing degradation of cAMP. The corresponding increase in
-
M129587-25gProduct Application:It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. Milrinone inhibits the action of phosphodiesterase-3 preventing degradation of cAMP. The corresponding increase in
-
M129587-5gProduct Application:It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. Milrinone inhibits the action of phosphodiesterase-3 preventing degradation of cAMP. The corresponding increase in
-
M158694-100mgExplanationMinodronate is a third-generation bisphosphonate used clinically alone or in combination to treat osteoporosis. It is an inhibitor of farnesyl diphosphate synthase that acts as a bone resorption inhibitor.
-
M158694-1gExplanationMinodronate is a third-generation bisphosphonate used clinically alone or in combination to treat osteoporosis. It is an inhibitor of farnesyl diphosphate synthase that acts as a bone resorption inhibitor.
-
M158694-25mgExplanationMinodronate is a third-generation bisphosphonate used clinically alone or in combination to treat osteoporosis. It is an inhibitor of farnesyl diphosphate synthase that acts as a bone resorption inhibitor.
-
M158694-500mgExplanationMinodronate is a third-generation bisphosphonate used clinically alone or in combination to treat osteoporosis. It is an inhibitor of farnesyl diphosphate synthase that acts as a bone resorption inhibitor.